Inari Medical, Inc. Stock Price, News & Analysis

Inari Medical, Inc. (NASDAQ: NARI) will report its Q1 2023 financial results on May 3, 2023. The company focuses on innovative medical devices for treating venous diseases. A conference call and webcast will be held at 1:30 PM PT / 4:30 PM ET on the same day to discuss these results and recent company highlights. Interested parties can access the call via telephone or through the investor relations website. Inari Medical is committed to improving patient outcomes through education, clinical research, and innovative solutions for unmet health needs. The company aims to establish its treatments as the standard of care for venous thromboembolism.

Inari Medical, Inc. (NASDAQ: NARI) announced positive results from the FLAME study for high-risk pulmonary embolism (PE) during the 2023 ACC conference. This is the largest prospective study of interventional treatment in this patient group, historically facing a 25-50% mortality rate. The study showed a mortality rate of just 1.9% in patients treated with FlowTriever, a 90% reduction compared to the 29.5% rate in the control group. The trial's early termination highlights the significant effectiveness of FlowTriever, suggesting it may change clinical practice guidelines and improve survival rates for high-risk PE patients.

Inari Medical reported a strong financial performance for Q4 2022, generating $107.8 million in revenue, marking a 30% year-over-year increase. For the full year, revenue reached $383.5 million, a 38% increase compared to 2021. The net loss for Q4 was $5.8 million with a loss per share of $0.11. Operating expenses rose to $100.5 million, up from $73.2 million in Q4 2021, driven by increased headcount for expansion. Despite a decrease in gross margin, now at 87.8%, the company reaffirmed its 2023 revenue guidance of $470-480 million.

Inari Medical, Inc. (NASDAQ: NARI) announced the release date for its fourth quarter and full year 2022 financial results, set for February 27, 2023. Following the release, Inari will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss financial outcomes and recent developments. Interested parties can access the live call via phone or webcast through the Inari investor relations website. The company emphasizes its commitment to innovating solutions for unmet health needs and aims to establish its treatments as the standard of care for venous thromboembolism.

Inari Medical, Inc. (NASDAQ: NARI), a leading medical device company, will participate virtually in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 14, 2023. The company is dedicated to transforming patient care through innovative solutions for venous diseases and beyond. Inari’s ethos emphasizes patient-focused principles and a commitment to improving lives. They strive to establish their treatments as the standard of care for venous thromboembolism. For inquiries, investors can contact Caroline Corner at ICR Westwicke.

Inari Medical (NASDAQ: NARI) has announced the enrollment of the first patient in the DEFIANCE trial, a pivotal randomized controlled trial comparing the ClotTriever System with traditional anticoagulation for treating iliofemoral deep vein thrombosis (DVT). The trial aims to enroll 300 patients across 60 centers globally. Esteemed medical professionals lead the trial, which seeks to establish stronger evidence for DVT treatment methods. Inari has a strong commitment to advancing care for venous thromboembolism through ongoing clinical research.

Inari Medical, Inc. (NASDAQ: NARI) reported preliminary unaudited revenues for Q4 2022 between $107.0 million and $108.0 million, marking a 29% year-over-year increase, and full-year revenues expected between $382.7 million and $383.7 million, representing a 38% increase from 2021. The company projected 2023 revenue between $470 million and $480 million, reflecting a growth of approximately 23% to 25%. The results are preliminary and subject to audit revisions.